327 related articles for article (PubMed ID: 21854134)
1. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
2. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
3. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Rittenberg C; Sullivan S; Istwan N; Rhea D; Stanziano G; Newman R
Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
[TBL] [Abstract][Full Text] [Related]
4. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
6. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
Barton JR; Barton LA; Istwan NB; Rhea DJ; Desch CN; Sibai BM
Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
8. Preterm birth aetiology 2004-2008. Maternal factors associated with three phenotypes: spontaneous preterm labour, preterm pre-labour rupture of membranes and medically indicated preterm birth.
Henderson JJ; McWilliam OA; Newnham JP; Pennell CE
J Matern Fetal Neonatal Med; 2012 Jun; 25(6):642-7. PubMed ID: 21827362
[TBL] [Abstract][Full Text] [Related]
9. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
11. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
12. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
13. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
14. Appropriate antenatal corticosteroid use in women at risk for preterm birth before 34 weeks of gestation.
Mahony R; McKeating A; Murphy T; McAuliffe F; O'Herlihy C; Foley M
BJOG; 2010 Jul; 117(8):963-7. PubMed ID: 20465556
[TBL] [Abstract][Full Text] [Related]
15. Does the clinical presentation of a prior preterm birth predict risk in a subsequent pregnancy?
Drassinower D; Običan SG; Siddiq Z; Heller D; Gyamfi-Bannerman C; Friedman AM
Am J Obstet Gynecol; 2015 Nov; 213(5):686.e1-7. PubMed ID: 26215326
[TBL] [Abstract][Full Text] [Related]
16. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
17. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Ventolini G; Duke J; Po W; Barhan S; Rhea D; Desch C; Istwan N; Stanziano G
J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
[TBL] [Abstract][Full Text] [Related]
18. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Romero J; Rebarber A; Saltzman DH; Schwartz R; Peress D; Fox NS
Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
[TBL] [Abstract][Full Text] [Related]
19. The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
Rafael TJ; Mackeen AD; Berghella V
Am J Perinatol; 2011 May; 28(5):389-94. PubMed ID: 21380984
[TBL] [Abstract][Full Text] [Related]
20. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Rebarber A; Cleary-Goldman J; Istwan NB; Rhea DJ; Desch C; Russo-Stieglitz K; Saltzman DH
Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
